Atinary banked $12M (≈ €11.2M) in Seed funding led by Aglaé Ventures. The round includes participation from XAnge, ACE & Company, Venture Kick, and High-Tech Gründerfonds (HTGF).
The Lausanne-based company develops a "no-code" AI platform designed to accelerate R&D and innovation in the pharmaceutical and materials science sectors. Its technology, Atinary SDLabs, automates the experimental process, allowing researchers to optimise chemical reactions and material formulations with significantly fewer manual trials.
Founded by a team with experience from Palantir, Atinary aims to replace traditional trial-and-error methods in laboratories. The platform integrates with existing laboratory hardware to create autonomous workflows, often referred to as "self-driving labs", which can lead to faster discovery cycles for new drugs and sustainable materials.
The investment reflects a sustained interest in the intersection of AI and life sciences across the DACH region and France, as European VCs increasingly back deep-tech solutions that bridge the gap between software and physical laboratory infrastructure.
Originally reported by Tech Funding News.